<div id="readability-page-1"><div><p>On January 30, 2026, Amgen Inc. entered into a Termination Agreement with Kyowa Kirin Co. Ltd. pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the &#34;License and Collaboration Agreement&#34;). The termination of the License and Collaboration Agreement will become effective upon receipt of regulatory approval.</p><p>The foregoing description of the Termination Agreement and the termination of the License and collaboration agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference.</p></div></div>

<p>安進公司已與協和發酵株式會社簽署終止協議，以終止自 2021 年 6 月 1 日起生效的許可與合作協議。該終止將在獲得監管批准後生效。終止協議的詳細信息已在附件 10.1 中列出，供完整性參考</p>

Amgen Inc. Enters into A Termination Agreement with Kyowa Kirin Co., Ltd

marketscreener

Kyowa Kirin Co., Ltd.

Invesco Nasdaq Biotechnology ETF

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

安進

安進公司與協和麒麟株式會社達成終止協議